Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Toolgen Incorporated has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 5 distinct art units, so each application presents a separate examiner and technical examination context.
REGA, KYLE THOMAS is the busiest examiner, with 1 pending matter. Counsel should use centralized review to maintain consistent biotechnology terminology and disclosure support, while developing claim arguments independently for each matter. The assignment pattern does not support reliance on recurring examiner treatment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGA, KYLE THOMAS | 1 | 63.0% | +41.7% |
| KUBELIK, ANNE R | 1 | 75.8% | -1.1% |
| TINSLEY, BRENDAN THOMAS | 1 | 60.4% | +74.3% |
| ANGELL, JON E | 1 | 71.1% | +21.0% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19134147 | METHOD FOR PRODUCING CaAIBZ1 GENE-EDITED HOT PEPPER TO ENHANCE DROUGHT TOLERANCE | KUBELIK, ANNE R | — |
| 18822009 | HYPOIMMUNOGENIC STEM CELLS, HYPOIMMUNOGENIC CELLS DIFFERENTIATED OR DERIVED FROM STEM CELLS AND METHOD OF PREPARING SAME | TINSLEY, BRENDAN THOMAS | — |
| 18276794 | METHODS AND COMPOSITIONS FOR GENERATING STEM CELL-DERIVED IMMUNE CELLS WITH ENHANCED FUNCTION | ANGELL, JON E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17262342 | GENE EDITING OF ANTICOAGULANTS | MEYERING, SHABANA SHABBEER | 23d overdue |
| 19317342 | SINGLE BASE SUBSTITUTION PROTEIN, AND COMPOSITION COMPRISING SAME | REGA, KYLE THOMAS | — |
| 18822009 | HYPOIMMUNOGENIC STEM CELLS, HYPOIMMUNOGENIC CELLS DIFFERENTIATED OR DERIVED FROM STEM CELLS AND METHOD OF PREPARING SAME | TINSLEY, BRENDAN THOMAS | — |
| 18276794 | METHODS AND COMPOSITIONS FOR GENERATING STEM CELL-DERIVED IMMUNE CELLS WITH ENHANCED FUNCTION | ANGELL, JON E | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1663 | 1 |
| 1634 | 1 |
| 1641 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19317342 | SINGLE BASE SUBSTITUTION PROTEIN, AND COMPOSITION COMPRISING SAME | REGA, KYLE THOMAS | 1636 | §102 | Final Rejection | — | Pending | Sep 03, 2025 |
| 19134147 | METHOD FOR PRODUCING CaAIBZ1 GENE-EDITED HOT PEPPER TO ENHANCE DROUGHT TOLERANCE | KUBELIK, ANNE R | 1663 | §103§112 | Non-Final OA | — | Pending | May 29, 2025 |
| 18822009 | HYPOIMMUNOGENIC STEM CELLS, HYPOIMMUNOGENIC CELLS DIFFERENTIATED OR DERIVED FROM STEM CELLS AND METHOD OF PREPARING SAME | TINSLEY, BRENDAN THOMAS | 1634 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18276794 | METHODS AND COMPOSITIONS FOR GENERATING STEM CELL-DERIVED IMMUNE CELLS WITH ENHANCED FUNCTION | ANGELL, JON E | 1641 | §102§103 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 17262342 | GENE EDITING OF ANTICOAGULANTS | MEYERING, SHABANA SHABBEER | 1635 | §103 | Non-Final OA | 23d overdue | Pending | Jan 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialToolgen Incorporated has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Kyle Thomas Rega has the most, with 1 of Toolgen Incorporated's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
